• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ngm Biopharmaceuticals Inc (NQ: NGM )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ngm Biopharmaceuticals Inc

    < Previous 1 2 3 4 5 Next >
    INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    Why NGM Biopharmaceuticals Dived by 41% on Monday
    The results of a hepatitis drug candidate's clinical trial were not good. 
    Via The Motley Fool
    52 Biggest Movers From Yesterday
    Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
    Via Benzinga
    Exposures Product Safety
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
    Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The... 
    Via Benzinga
    Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
    Toward the end of trading Monday, the Dow traded up 0.75% to 34,462.98 while the NASDAQ rose 1.64% to 13,691.64. The S&P also rose, gaining 1.25% to 4,207.76. The U.S. has the... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
    Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5... 
    Via Benzinga
    Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
    Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    35 Stocks Moving In Monday's Mid-Day Session
    Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive... 
    Via Benzinga
    Exposures Product Safety
    Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma
    Following the market opening Monday, the Dow traded up 0.50% to 34,378.59 while the NASDAQ rose 1.18% to 13,629.81. The S&P also rose, gaining 0.83% to 4,190.35. The U.S. has... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops
    NGM Biopharmaceuticals joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market session. The market value of their outstanding shares is... 
    Via Benzinga
    NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
    NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (... 
    Via Benzinga
    NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
    NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date... 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.